8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Dec 14, 2017)

Filed December 14, 2017For Securities:PFE

Summary

Pfizer Inc. (PFE) announced on December 14, 2017, the pricing of its private offer to exchange outstanding £1,500,000,000 6.500 per cent. Notes due 2038 (the "2038 Notes") for newly issued debt securities. Concurrently, the company also initiated a tender offer to purchase any and all of these same 2038 Notes for cash. These offers, collectively referred to as the "2038 Notes Offers," were set to expire on December 14, 2017. This filing indicates Pfizer's strategic initiative to manage its outstanding debt obligations, potentially optimizing its capital structure by replacing existing notes with new debt instruments or by repurchasing them. Investors should note the significant principal amount involved in the 2038 Notes and the imminent expiration of these offers, which could signal a shift in the company's debt profile and financial strategy.

Key Highlights

  • 1Pfizer priced an offer to exchange its £1.5 billion 6.500% Notes due 2038 for new debt securities.
  • 2Pfizer also launched a tender offer to repurchase its outstanding 2038 Notes for cash.
  • 3Both the exchange offer and the tender offer (collectively, the '2038 Notes Offers') were for any and all outstanding 2038 Notes.
  • 4The 2038 Notes Offers were set to expire on December 14, 2017, the same day the 8-K was filed.
  • 5The company's press release announcing the pricing of these offers is included as Exhibit 99.1.
  • 6This action suggests a proactive approach by Pfizer to manage its debt portfolio.

Frequently Asked Questions

The primary purpose of the '2038 Notes Offers' is for Pfizer to manage its outstanding debt. The company is offering to exchange its existing £1.5 billion 6.500% Notes due 2038 for newly issued debt securities, and simultaneously offering to purchase these notes for cash. This allows Pfizer to potentially restructure its debt, reduce interest expense, or adjust its debt maturity profile.

The notes involved are Pfizer's outstanding £1,500,000,000 6.500 per cent. Notes due 2038. This represents a principal amount of approximately £1.5 billion (or about $2 billion USD at prevailing exchange rates at the time).

The 2038 Notes Offers were set to expire on December 14, 2017, at 5:00 p.m. (New York time), which was the same day the company announced the pricing and filed this 8-K report.

Investors holding Pfizer's 2038 Notes would have needed to review the terms and conditions of both the exchange offer and the tender offer, and make a decision on whether to participate before the expiration deadline of December 14, 2017. The press release (Exhibit 99.1) would contain the detailed information required to make an informed decision.